CD33 and acute myeloid leukemia: After the spontaneous withdrawal of the manufacturer due to the lack of survival improvement and the high induction mortality, the anti-CD33-calicamycin conjugate gemtuzumab-ozogamicin (GO) has been revived for core binding factor (CBF) AMLs and for elderly patients with AML or high-risk myelodysplastic syndrome (MDS), where it has demonstrated reduced relapse risk and survival advantage in patients with favorable and intermediate cytogenetic risk [81].